证券代码：600420 证券简称：国药现代 公告编号：2025-032 上海现代制药股份有限公司 关于全资子公司药品通过仿制药一致性评价的自愿性信息 披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准硫酸镁注射液增加规格并通过仿制药质量和疗效 一致性评价（以下简称一致性评价）。现将相关情况公告如下： 规格：10ml:5g 通知书编号：2025B01513 药品批准文号：国药准字 H20258054 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：注射剂仿制药质量和疗效一致性评价，其他变更事项包括：增加 规格。 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗效 一致性评价工作有关事项的公告》（2017 年第 100 ...

国药现代（600420）公告，全资子公司国药集团容生制药有限公司的硫酸镁注射液通过仿制药质量和疗 效一致性评价，并增加10ml:5g规格。2023年硫酸镁注射液全国公立医疗机构销售额为2.78亿元。国药 容生累计研发投入约612.79万元。本次通过一致性评价将丰富公司血液和造血系统用药产品群，增强市 场竞争力，对公司未来发展产生积极影响。 ...

关于上海现代制药股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对上海现代制药股份有限公司（以下简称"国药现代""公司""上 市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本持续督导期 间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 中信证券股份有限公司 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 丁元、黄江宁 （三）现场检查人员 黄江宁、赵贤耀 （四）现场检查时间 2025 年 3 月 31 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 （六）现场检查手段 1 本次现场检查的手段主要包括资料查阅、访谈、现场 ...

经中国证券监督管理委员会《关于核准上海现代制药股份有限公司非公开发 行股票的批复》（证监许可〔2022〕3065 号）核准，并经上海证券交易所同意， 公司于 2022 年 12 月 29 日以非公开发行股票的方式向中国医药集团有限公司发 行了人民币普通股股票 145,102,781 股，每股价格为每股人民币 8.27 元。本次非 公开发行股票募集资金总额为人民币 1,199,999,998.87 元，扣除与发行有关的费 用 13,084,635.86 元后，募集资金净额为 1,186,915,363.01 元。大华会计师事务所 （特殊普通合伙）于 2022 年 12 月 30 日对上海现代制药股份有限公司 2022 年度 非公开发行股票的资金到位情况进行了审验，并出具了"大华验字〔2022〕000955 号"验资报告。 中信证券股份有限公司 关于上海现代制药股份有限公司 2024年度持续督导报告书 | 上市公司：上海现代制药股份有限公司（以下简称"国药现代"、"公司"） | | | --- | --- | | 保荐人名称：中信证券股份有限公司（以下简称"中信证券"或"保荐人"） | | | 保荐代表人姓名：丁 ...

中信证券股份有限公司关于 上海现代制药股份有限公司非公开发行股票持续督导 保荐总结报告书 保荐人编号：Z20374000 申报时间：2025 年 4 月 | 公司名称 | 上海现代制药股份有限公司 | | --- | --- | | 英文名称 | Shanghai Shyndec Pharmaceutical Co., Ltd. | | 统一社会信用代码 | 91310000630459924R | | 注册资本 | 元人民币 1,341,172,692 | | 法定代表人 | 许继辉 | | 成立日期 | 1996-11-27 | | 上市日期 | 2004-6-16 | | 注册地址 | 上海市浦东新区建陆路 378 号 | | 办公地址 | 上海市浦东新区建陆路 378 号 | | 证券代码 | 600420.SH | | 证券简称 | 国药现代 | 一、发行人基本情况 二、本次发行情况概述 经中国证券监督管理委员会《关于核准上海现代制药股份有限公司非公开发 行股票的批复》（证监许可〔2022〕3065 号）核准，并经上海证券交易所同意， 公司于 2022 年 12 月 29 日以非公开发行股票的方式向 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-031 上海现代制药股份有限公司 关于全资孙公司获得化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产企业：江苏威奇达药业有限公司 企业地址：南通市海门区临江镇临江大道 1 号 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 近日，上海现代制药股份有限公司（以下简称公司）全资孙公司江苏威奇达 药业有限公司(以下简称国药江苏威奇达)收到国家药品监督管理局核准签发的 《化学原料药上市申请批准通知书》，批准原料药枸橼酸托法替布上市申请，现 将相关情况公告如下： 一、化学原料药基本信息 化学原料药名称：枸橼酸托法替布 登记号：Y20230000702 通知书编号：2025YS00284 化学原料药注册标准编号：YBY62492025 包装规格：5kg/听 本次国药江苏威奇达的枸橼酸托法替布原料药获得上市申请批准，表明该原 料药符合国家相关药 ...

Summary of Guoyao Modern's Conference Call Company Overview - **Company**: Guoyao Modern - **Industry**: Pharmaceutical, specifically focusing on generic drugs and active pharmaceutical ingredients (APIs) Key Financial Performance - **Revenue**: 10.9 billion CNY, a decrease of 9.38% year-on-year [3] - **Net Profit**: 1.084 billion CNY, an increase of 56.6% year-on-year, with a five-year compound annual growth rate (CAGR) of 13.68% [3] - **Gross Margin**: Increased by 0.92 percentage points to 39.2% [3] - **Weighted ROE**: Reached 8.45%, an increase of 2.43 percentage points [3] - **Earnings per Share**: 0.81 CNY [3] - **Cash Flow**: Operating cash flow accounted for 20.63% of revenue, an increase of 6.38 percentage points [3] - **Debt Ratio**: Decreased to 23.22%, down 2.69 percentage points [4] Business Segment Performance Intermediate and API Business - **Revenue**: 5.198 billion CNY, an increase of 8.54% year-on-year [5] - **Core Products**: 85% of revenue from anti-infection products, with penicillin products growing by 20% and clavulanic acid series by 33%, while cephalosporin products declined by 32% [5] - **Export**: Nearly 80% of anti-infection products are for export [5] Formulation Business - **Revenue**: Decreased by over 20% [5] - **Profitability**: Maintained through cost control and changes in business model [5] - **Product Composition**: Anti-infection formulations account for 38%, cardiovascular and neurological formulations each account for 12% [5] Research and Development - **R&D Investment**: 600 million CNY, representing 6% of revenue [6] - **Projects**: 210 projects in progress, with 70% focused on new products [6] - **Focus Areas**: Emphasis on narcotics, anti-infection, cardiovascular, and oncology fields [6] Future Outlook - **2025 Revenue Projection**: Expected to reach 11.3 billion CNY, a growth of approximately 3% [7] - **Strategic Focus**: Digital empowerment, marketing reform, and optimization of industrial layout to enhance competitiveness [7] - **Chronic Disease Focus**: Concentration on cardiovascular, metabolic, and endocrine diseases under the backdrop of centralized procurement [10] Market Trends and Risks - **Raw Material Market**: Subject to global demand fluctuations, with potential price volatility due to supply-demand dynamics [8] - **Antibiotic Product Pricing**: Stable decline in prices observed in Q1, with expected demand reduction in summer months [9] - **Cost Management**: Strategies include capacity optimization, product structure adjustment, and strategic partnerships to mitigate cost impacts [11] Strategic Initiatives - **New Product Development**: Focus on high-value, technically challenging products, including first generic drugs and improved new drugs [10] - **Acquisition Plans**: Over 80 products under review, focusing on infection, cardiovascular, and neurological areas [12] - **Sales Strategy**: Emphasis on maintaining a stable sales expense ratio, currently around 10% [22] Conclusion Guoyao Modern is navigating a challenging pharmaceutical landscape with a strategic focus on enhancing profitability through R&D, cost management, and market adaptation. The company is poised for moderate growth in 2025 while addressing potential market risks and leveraging its strengths in high-demand therapeutic areas.

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of 1,083,622,881.88 CNY for the fiscal year 2024[4]. - The company achieved operating revenue of CNY 10.94 billion in 2024, a decrease of 9.38% compared to the previous year[21]. - Net profit attributable to shareholders reached CNY 1.08 billion, an increase of 56.62% year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1.04 billion, up 52.72% from the previous year[22]. - The total operating income decreased by 9.38% to approximately 10.94 billion RMB, while operating costs decreased by 10.73% to approximately 6.65 billion RMB[61]. - The company reported a net profit attributable to shareholders of 1.094 billion RMB, a year-on-year increase of 56.62%, with a return on equity increasing by 2.43 percentage points[59]. - The company reported a significant reduction in sales expenses due to a transformation in marketing models and better cost control[64]. - The overall gross margin improved to 39.24%, an increase of 0.91 percentage points year-on-year[64]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares (including tax), totaling 268,234,538.40 CNY based on a total share capital of 1,341,172,692 shares as of December 31, 2024[4]. - The total cash dividend amount for 2024 is CNY 402,351,807.60, which accounts for 37.13% of the net profit attributable to ordinary shareholders in the consolidated financial statements[184]. - The cumulative cash dividend amount over the last three accounting years is CNY 670,586,346.00, with a cash dividend ratio of 83.71% based on the average annual net profit of CNY 801,099,402.09[186]. Research and Development - The company invested CNY 675 million in R&D, accounting for 6.17% of operating revenue, an increase of 0.41 percentage points year-on-year[33]. - The total R&D expenditure amounted to ¥674,510,524.59, representing 6.17% of total revenue, with capitalized R&D accounting for 14.62%[75]. - The company launched 31 new research projects in 2024 and filed 11 provincial-level research applications, indicating a focus on innovation[34]. - The company applied for 39 patents and received 62 patents in 2024, including 34 invention patents[99]. - The company is committed to enhancing its research and development capabilities, as indicated by the significant investments in various therapeutic areas[111]. Market Position and Sales - The company ranked 13th in the "Top 100 Chinese Chemical Pharmaceutical Enterprises" list for 2023, reflecting its strong market position[39]. - Export sales revenue reached RMB 3.99 billion, a year-on-year growth of 25.95%, with the intermediates and APIs segment growing by 28.19%[34]. - The formulation segment achieved sales revenue of 5.451 billion RMB, a year-on-year decrease of 20.24%, accounting for 49.84% of total revenue, down 6.78 percentage points from the previous year[49]. - Sales revenue in the nervous system medication area decreased by 8.28% despite significant growth in the sales of certain products, with injection of fentanyl hydrochloride and minaprine tablets increasing by 22.64% and 33.58% respectively[49]. Risk Management and Compliance - There are no significant risks that materially affect the company's production and operations during the reporting period[6]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[6]. - The company has not violated decision-making procedures for providing guarantees to external parties[6]. - The company emphasizes compliance and risk control, aiming to enhance internal control and supervision mechanisms to support stable development[133]. Governance and Management - The company has established a comprehensive governance structure with clear responsibilities for the shareholders' meeting, board of directors, and supervisory board, ensuring effective decision-making and oversight[141]. - The board of directors consists of 9 members, including 7 external directors, and has established specialized committees to facilitate effective governance and decision-making[142]. - The company has implemented a performance-based evaluation mechanism for senior management, linking compensation to operational performance[187]. - The total pre-tax remuneration for the management team during the reporting period amounted to 934.32 million CNY[152]. Environmental Protection - The company has established a comprehensive environmental protection regulatory system across its key pollutant discharge units, enhancing management efficiency in environmental protection[196]. - All key pollutant discharge units are equipped with advanced environmental protection facilities, including internal wastewater treatment systems and air emission terminal treatment facilities, which are operating stably[196]. - The company has implemented a strict "three simultaneous" system for environmental protection in construction projects, ensuring compliance throughout the project lifecycle[197]. - The company has a monitoring system in place to ensure that pollutant emissions meet environmental standards consistently[197]. Strategic Initiatives - The company is committed to becoming an innovation-driven leader in the pharmaceutical industry, focusing on key therapeutic areas such as anti-infection and cardiovascular health[40]. - The company is actively adjusting its business layout and enhancing operational quality and efficiency in response to market changes and competitive pressures[46]. - The company plans to enhance its innovation capabilities in the pharmaceutical sector, aligning with government initiatives to promote modern industrial systems[86]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal by Q1 2024[153].

上海现代制药股份有限公司 2024 年度报告摘要 公司代码：600420 公司简称：国药现代 上海现代制药股份有限公司 2024 年度报告摘要 上海现代制药股份有限公司 2024 年度报告摘要 第一节 重要提示 1、 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到 www.sse.com.cn 网站仔细阅读年度报告全文。 2、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 魏树源 | 工作原因 | 许继辉 | 4、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度实现合并归属于上市公司股东的 净利润 1,083,622,881. ...

证券代码：600420 证券简称：国药现代 公告编号：2025-025 证券代码：600420 证券简称：国药现代 公告编号：2025-025 上海现代制药股份有限公司 关于申请综合授信的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）于 2025 年 3 月 26 日召开第八 届董事会第二十次会议，审议通过了《关于申请综合授信的议案》，该议案尚需 提交公司 2024 年年度股东大会审议。 为满足公司日常生产经营及相关项目建设、投资等的资金需求，根据公司 2025 年度资金预算，公司拟向国有及商业股份制银行申请 1,357,020.00 万元综合 授信（含为子公司提供的担保授信），主要用于流动资金贷款、开立票据、保函、 信用证及并购贷款等融资业务。预计明细如下： | 序号 | 授信银行 | 授信额度（万元） | | --- | --- | --- | | 1 | 中国工商银行股份有限公司 | 45,000.00 | | 2 | 广发银行股份有限公司 | 19,900.00 | | ...